Earnings

All articles by Earnings

Q3 pharma earnings roundup: Moderna, Regeneron and Teva
Q3 pharma earnings roundup: Moderna, Regeneron and Teva
Jack O'Brien
November 3, 2022
1:00 pm

Several other healthcare companies reported, including Agios, SpringWorks and Bausch Health.

Surface Oncology trims workforce by 20%
Surface Oncology trims workforce by 20%
Jack O'Brien
November 2, 2022
2:32 pm

Company management stated that its financial runway is now sufficient to get into Q2 2024.

Haleon releases first earnings since GSK spin off, rebuffs Zantac claims
Haleon releases first earnings since GSK spin off, rebuffs Zantac claims
Jack O'Brien
September 20, 2022
2:36 pm

The standalone company benefited from the strong performance of several key products, including Theraflu, Advil and Centrum.

McKinsey: Good financial times ahead for healthcare firms
McKinsey: Good financial times ahead for healthcare firms
Lecia Bushak
August 3, 2022
3:46 pm

After the pandemic years of 2020 and 2021 and the inflation of 2022, researchers expect growth in 2023.

Bayer’s pharma sales rise thanks to Nubeqa and radiology business
Bayer’s pharma sales rise thanks to Nubeqa and radiology business
Jack O'Brien
May 10, 2022
10:30 am

The company released its earnings less than two weeks after its CEO survived a non-binding shareholder vote.

Moderna reports $6.1B in revenue, Regeneron earnings led by Dupixent sales
Moderna reports $6.1B in revenue, Regeneron earnings led by Dupixent sales
Jack O'Brien
May 4, 2022
10:22 am

Regeneron’s revenues rose by double digits, though its net income fell by double digits.

Earnings season continues with Biogen bust, Pfizer boom
Earnings season continues with Biogen bust, Pfizer boom
Jack O'Brien
May 3, 2022
10:42 am

Biogen CEO and Aduhelm out; Paxlovid generates $1.5B in sales for Pfizer.

Pharma earnings roundup: AstraZeneca, BMS, AbbVie report
Pharma earnings roundup: AstraZeneca, BMS, AbbVie report
Jack O'Brien
April 29, 2022
12:33 pm

Notably, AstraZeneca said that total revenue from its COVID-19 medicines is likely to decline by a “low-to-mid twenties percentage.”

Gilead Q1 revenue surges to $6.6B on increased demand for Biktarvy and Veklury
Gilead Q1 revenue surges to $6.6B on increased demand for Biktarvy and Veklury
Jack O'Brien
April 29, 2022
9:12 am

Despite top-line growth, sales for Truvada and hep-C products fell by double-digits.

Merck records nearly $16B in sales, Eli Lilly revenues grow 15%
Merck records nearly $16B in sales, Eli Lilly revenues grow 15%
Jack O'Brien
April 28, 2022
10:29 am

Lilly generated $660 million in revenue from its COVID antibody treatment, while Merck’s oral antiviral treatment produced sales of $3.2 billion.

  • From Our Partners